Repurposing Auranofin as a Lead Candidate for Treatment of Lymphatic Filariasis and Onchocerciasis

PLoS Neglected Tropical Diseases

Volumn 9, Issue 2, 2015, Pages

  Bulman, Christina A ^a   Bidlow, Chelsea M ^a   Lustigman, Sara ^b   Cho Ngwa, Fidelis ^c   Williams, David ^d   Rascón, Jr, Alberto A ^a,e   Tricoche, Nancy ^b   Samje, Moses ^c   Bell, Aaron ^b   Suzuki, Brian ^a   Lim, K C ^a   Supakorndej, Nonglak ^f   Supakorndej, Prasit ^g   Wolfe, Alan R ^h   Knudsen, Giselle M ^h   Chen, Steven ^h   Wilson, Chris ^h   Ang, Kean Hooi ^h   Arkin, Michelle ^h   Gut, Jiri ^a   Franklin, Chris ^a   Marcellino, Chris ⁱ   McKerrow, James H ^j   Debnath, Anjan ^j   Sakanari, Judy A ^a   more..

^a University of California at San Francisco   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c UNIVERSITY OF BUEA   (Cameroon)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e SAN JOSE STATE UNIVERSITY   (United States)

^f FilariaTech ^*  (United States)

^g UNIVERSITY OF GEORGIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; FLUBENDAZOLE; THIOREDOXIN REDUCTASE; ALBENDAZOLE; ANTHELMINTIC AGENT; ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE; IVERMECTIN;

ADULT; ANIMAL TISSUE; ARTICLE; BRUGIA MALAYI; BRUGIA PAHANGI; CONTROLLED STUDY; DRUG SCREENING; FEMALE; HUMAN; IC50; LOA LOA; LYMPHATIC FILARIASIS; MALE; MICROBIAL VIABILITY; MOVEMENT (PHYSIOLOGY); MTT ASSAY; NONHUMAN; ONCHOCERCA; ONCHOCERCA OCHENGI; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BOVINE; CELL LINE; DRUG EFFECTS; DRUG REPOSITIONING; ELEPHANTIASIS, FILARIAL; GERBIL; HAPLORHINI; LOA; LOIASIS; MICROFILARIA (NEMATODE LARVA); PARASITOLOGY;

ADULT; ALBENDAZOLE; ANIMALS; ANTHELMINTICS; AURANOFIN; BRUGIA MALAYI; CATTLE; CELL LINE; DIETHYLCARBAMAZINE; DRUG REPOSITIONING; ELEPHANTIASIS, FILARIAL; FEMALE; FILARICIDES; GERBILLINAE; HAPLORHINI; HUMANS; IVERMECTIN; LOA; LOIASIS; MICROFILARIAE; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS;

EID: 84924024885     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003534     Document Type: Article

References (56)

1. World Health Organization (2014) Lymphatic Filariasis Fact Sheet. URL< http://www.who.int/mediacentre/factsheets/fs102/en/ >
2. USAID’s NTD Program (2014) Onchocerciasis or River Blindness. URL< http://www.neglecteddiseases.gov/target_diseases/onchocerciasis/ >
3. Plaisier AP, Van Oortmarssen GJ, Remme J, JD H, (1991) The reproductive lifespan of Onchocerca volvulus in West African savanna. Acta Tropica 48: 271–284. 1674401
4. Taylor MJ, Hoerauf A, Bockarie M, (2010) Lymphatic filariasis and onchocerciasis. Lancet 376: 1175–1185. doi: 10.1016/S0140-6736(10)60586-7 20739055
5. Addiss DG, Brady MA, (2007) Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J 6: 2. 17302976
6. Hoerauf A, Pfarr K, Mand S, Debrah AY, Specht S, (2011) Filariasis in Africa—treatment challenges and prospects. Clin Microbiol Infect 17: 977–985. doi: 10.1111/j.1469-0691.2011.03586.x 21722251
7. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, et al. (1997) Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350: 18–22. 9217715
8. Carme B, Boulesteix J, Boutes H, Puruehnce MF, (1991) Five cases of encephalitis during treatment of loiasis with diethylcarbamazine. Am J Trop Med Hyg 44: 684–690. 1858969
9. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP, (2003) Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2 Suppl 1: S4. 14975061
10. Specht S, Debrah AY, Klarmann U, Mand S, Hoerauf A, Pfarr K, (2013) Chemotherapy of filariasis—established strategies and new developments. GMS Infectious Diseases 1.
11. Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC, (2014) A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis 8: e2953. doi: 10.1371/journal.pntd.0002953 24968000
12. Marcellino C, Gut J, Lim KC, Singh R, McKerrow J, et al. (2012) WormAssay: A Novel Computer Application for Whole-Plate Motion-based Screening of Macroscopic Parasites. PLOS Neglected Tropical Diseases 6: e1494. doi: 10.1371/journal.pntd.0001494 22303493
13. Renz A, Trees AJ, Achu-Kwi D, Edwards G, Wahl G, (1995) Evaluation of suramin, ivermectin and CGP 20376 in a new macrofilaricidal drug screen, Onchocerca ochengi in African cattle. Trop Med Parasitol 46: 31–37. 7631125
14. Trees AJ, Graham SP, Renz A, Bianco AE, Tanya V, (2000) Onchocerca ochengi infections in cattle as a model for human onchocerciasis: recent developments. Parasitology 120 Suppl: S133–142. 10874716
15. Manchang TK, Ajonina-Ekoti I, Ndjonka D, Eisenbarth A, Achukwi MD, et al. (2014) Immune recognition of Onchocerca volvulus proteins in the human host and animal models of onchocerciasis. J Helminthol: 1–12.
16. Finkelstein AE, Walz DT, Batista V, Mizraji M, Roisman F, et al. (1976) Auranofin: New oral gold compound for treatment of rheumatoid arthritis. Ann Rheum Dis 35: 251–257. 791161
17. Katz WA, Alexander S, Bland JH, Blechman W, Bluhm GB, et al. (1982) The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol Suppl 8: 173–178. 6813481
18. Madeira JM, Gibson DL, Kean WF, Klegeris A, (2012) The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 20: 297–306. doi: 10.1007/s10787-012-0149-1 22965242
19. Bhabak KP, Bhuyan BJ, Mugesh G, (2011) Bioinorganic and medicinal chemistry: aspects of gold(I)-protein complexes. Dalton Trans 40: 2099–2111. doi: 10.1039/c0dt01057j 21321730
20. Furst DE, (1983) Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin: an orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy 3: 284–298. 6417628
21. Blodgett RC, Jr.Heuer MA, Pietrusko RG, (1984) Auranofin: a unique oral chrysotherapeutic agent. Semin Arthritis Rheum 13: 255–273. 6427927
22. Kean WF, Hart L, Buchanan WW, (1997) Auranofin. Br J Rheumatol 36: 560–572. 9189058
23. Prometheus Laboratories Inc. (2007) Ridaura (package insert).
24. Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, et al. (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 284: 28977–28985. doi: 10.1074/jbc.M109.020701 19710012
25. Rigobello MP, Messori L, Marcon G, Agostina Cinellu M, Bragadin M, et al. (2004) Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. J Inorg Biochem 98: 1634–1641. 15458826
26. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, et al. (2012) A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 18: 956–960. doi: 10.1038/nm.2758 22610278
27. Cho-Ngwa F, Abongwa M, Ngemenya MN, Nyongbela KD, (2010) Selective activity of extracts of Margaritaria discoidea and Homalium africanum on Onchocerca ochengi. BMC Complement Altern Med 10: 62. doi: 10.1186/1472-6882-10-62 21029456
28. Franz M, Zahner H, Benten P, (1990) Fine-structure alterations in female Brugia malayi and Litomosoides carinii after in vivo treatment with flubendazole. Parasitol Res 76: 401–405. 2352917
29. Arner ES, Sarioglu H, Lottspeich F, Holmgren A, Bock A, (1999) High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J Mol Biol 292: 1003–1016. 10512699
30. Rengby O, Johansson L, Carlson LA, Serini E, Vlamis-Gardikas A, et al. (2004) Assessment of production conditions for efficient use of Escherichia coli in high-yield heterologous recombinant selenoprotein synthesis. Appl Environ Microbiol 70: 5159–5167. 15345395
31. Huang HH, Day L, Cass CL, Ballou DP, Williams CH, Jr.et al. (2011) Investigations of the catalytic mechanism of thioredoxin glutathione reductase from Schistosoma mansoni. Biochemistry 50: 5870–5882. doi: 10.1021/bi200107n 21630672
32. Gromer S, Arscott LD, Williams CH, Jr.Schirmer RH, Becker K, (1998) Human placenta thioredoxin reductase: Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273: 20096–20101. 9685351
33. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, et al. (2007) Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 4: e206. 17579510
34. Lok JB, Abraham D, (1992) Animal models for the study of immunity in human filariasis. Parasitology Today 8: 168–171. 15463607
35. Duke BO, (1980) Observations on Onchocerca volvulus in experimentally infected chimpanzees. Tropenmed Parasitol 31: 41–54. 7376251
36. Eberhard ML, Dickerson JW, Boyer AE, Tsang VC, Zea-Flores R, et al. (1991) Experimental Onchocerca volvulus infections in mangabey monkeys (Cercocebus atys) compared to infections in humans and chimpanzees (Pan troglodytes). Am J Trop Med Hyg 44: 151–160. 2012258
37. Xie H BO, Williams SA, (1994) Molecular phylogenetic studies on filarial parasites based on 5S ribosomal spacer sequences. Parasite 1: 141–151. 9140481
38. Mehlhorn H, (2008) Filariidae. In: Encyclopedia of Parasitology: Springer Berlin Heidelberg. pp. 522–522.
39. Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A, et al. (2013) A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother 57: 2029–2035. doi: 10.1128/AAC.01675-12 23403423
40. Liu J, Hu W, Xu B, Wang JP, Wang SQ, et al. (2012) [Schistosomicidal mechanism of auranofin on Schistosoma japonicum and its cytotoxicity]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 30: 450–454. 23484256
41. Caroli A, Simeoni S, Lepore R, Tramontano A, Via A, (2012) Investigation of a potential mechanism for the inhibition of SmTGR by Auranofin and its implications for Plasmodium falciparum inhibition. Biochem Biophys Res Commun 417: 576–581. doi: 10.1016/j.bbrc.2011.12.009 22177949
42. Song L, Li J, Xie S, Qian C, Wang J, et al. (2012) Thioredoxin glutathione reductase as a novel drug target: evidence from Schistosoma japonicum. PLoS One 7: e31456. doi: 10.1371/journal.pone.0031456 22384025
43. Bonilla M, Denicola A, Novoselov SV, Turanov AA, Protasio A, et al. (2008) Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione. J Biol Chem 283: 17898–17907. doi: 10.1074/jbc.M710609200 18408002
44. Martinez-Gonzalez JJ, Guevara-Flores A, Alvarez G, Rendon-Gomez JL, Del Arenal IP, (2010) In vitro killing action of auranofin on Taenia crassiceps metacestode (cysticerci) and inactivation of thioredoxin-glutathione reductase (TGR). Parasitol Res 107: 227–231. doi: 10.1007/s00436-010-1867-1 20431894
45. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, et al. (2008) New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications. FEBS Lett 582: 844–847. doi: 10.1016/j.febslet.2008.02.028 18294965
46. Sharlow ER, Leimgruber S, Murray S, Lira A, Sciotti RJ, et al. (2014) Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity. ACS Chem Biol 9: 663–672. doi: 10.1021/cb400800q 24328400
47. Lobanov AV, Gromer S, Salinas G, Gladyshev VN, (2006) Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Res 34: 4012–4024. 16914442
48. Debnath A, Ndao M, Reed SL, (2013) Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes 4: 66–71. doi: 10.4161/gmic.22596 23137963
49. Andrade RM, Chaparro JD, Capparelli E, Reed SL, (2014) Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. PLoS Negl Trop Dis 8: e2973. doi: 10.1371/journal.pntd.0002973 25079790
50. Arner ES, Holmgren A, (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102–6109. 11012661
51. Kunchithapautham K, Padmavathi B, Narayanan RB, Kaliraj P, Scott AL, (2003) Thioredoxin from Brugia malayi: Defining a 16-Kilodalton Class of Thioredoxins from Nematodes. Infection and Immunity 71: 4119–4126. 12819103
52. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, et al. (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42: 872–881. 17320769
53. Sayed AA, Cook SK, Williams DL, (2006) Redox balance mechanisms in Schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets. J Biol Chem 281: 17001–17010. 16606626
54. Lawrence RA, Allen JE, Osborne J, Maizels RM, (1994) Adult and microfilarial stages of the filarial parasite Brugia malayi stimulate contrasting cytokine and Ig isotype responses in BALB/c mice. J Immunol 153: 1216–1224. 7913112
55. Zang X, Atmadja AK, Gray P, Allen JE, Gray CA, et al. (2000) The serpin secreted by Brugia malayi microfilariae, Bm-SPN-2, elicits strong, but short-lived, immune responses in mice and humans. J Immunol 165: 5161–5169. 11046048
56. Gunatilleke SS, Barrios AM, (2006) Inhibition of lysosomal cysteine proteases by a series of Au(I) complexes: a detailed mechanistic investigation. J Med Chem 49: 3933–3937. 16789749